ARTICLE
14 August 2026

Florida Launches Antitrust Investigation Into CVS Health And PBM Caremark

HB
Hall Benefits Law

Contributor

Strategically designed, legally compliant benefit plans are the cornerstone of long-term business stability and growth. As such, HBL provides comprehensive legal guidance on benefits in M&A, ESOPs, executive compensation, health and welfare benefits, retirement plans, and ERISA litigation matters. Responsive, relationship-driven counsel is the calling card of the Firm.
Florida's Attorney General has launched an antitrust investigation into CVS Health and its pharmacy benefit manager Caremark, examining whether the company inappropriately steered patients to CVS pharmacies and reimbursed them at higher rates than independent pharmacies. The investigation, part of a broader multi-state scrutiny of PBM business practices, seeks documents and testimony on policies related to transparency, reimbursement rates, audits, and market concentration in an industry where three PBMs co
United States Florida Antitrust/Competition Law
Hall Benefits Law are most popular:
  • within Antitrust/Competition Law and Insurance topic(s)

Florida’s Attorney General has announced an antitrust investigation into CVS Health and Caremark, CVS’s wholly owned pharmacy benefit manager (PBM). Similar investigations are occurring in multiple states over PBMs’ business practices, including issues related to transparency, reimbursement, and market concentration. Arkansas and Tennessee have even enacted state laws to limit pharmacy ownership of PBMs, although those laws face legal challenges.

To that end, the Florida Attorney General has issued a Civil Investigative Demand for documents and witness testimony concerning PBM policies and procedures. More specifically, the investigation is focusing on whether Caremark inappropriately steered patients to CVS pharmacies and reimbursed CVS pharmacies at higher rates than it did for independent pharmacies. The investigation also seeks information on audits in which Caremark allegedly clawed back payments made to pharmacies or otherwise utilized contracts to harm independent businesses. Finally, Florida has asked for information on reimbursement rates, pharmacy contracts, rebates, audits, and expansion plans, giving CVS until July 28, 2026, to reply.

For its part, CVS says that it will cooperate with the Attorney General’s investigation to address its concerns. CVS continues to argue that drug manufacturers, not PBMs, determine prescription medication prices. CVS also states that it maintains relationships with independent pharmacies as part of its Caremark pharmacy networks.

PBMs serve as intermediaries between plans, employers, pharmacies, and drug manufacturers. Their main functions are to negotiate drug prices, administer formularies, and handle reimbursement to pharmacies for prescription drug claims. Caremark is one of the three largest PBMs in the nation, which collectively process about 80% of all prescriptions issued in the U.S.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More